Illumina Past Earnings Performance

Past criteria checks 0/6

Illumina's earnings have been declining at an average annual rate of -55.7%, while the Life Sciences industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 6.7% per year.

Key information

-55.7%

Earnings growth rate

-55.7%

EPS growth rate

Life Sciences Industry Growth21.5%
Revenue growth rate6.7%
Return on equity-74.6%
Net Margin-36.1%
Last Earnings Update29 Sep 2024

Recent past performance updates

Recent updates

Illumina And Grail In 2025? Grounds For Optimism, If Mistakes Aren't Repeated

Dec 19

What Does Illumina, Inc.'s (NASDAQ:ILMN) Share Price Indicate?

Dec 12
What Does Illumina, Inc.'s (NASDAQ:ILMN) Share Price Indicate?

Calculating The Intrinsic Value Of Illumina, Inc. (NASDAQ:ILMN)

Nov 24
Calculating The Intrinsic Value Of Illumina, Inc. (NASDAQ:ILMN)

Illumina: Q3 Confirms Improving Fundamentals

Nov 05

We Think Illumina (NASDAQ:ILMN) Can Stay On Top Of Its Debt

Oct 21
We Think Illumina (NASDAQ:ILMN) Can Stay On Top Of Its Debt

Illumina Sees The Light: GRAIL Is Gone, Focus Restored (Rating Upgrade)

Aug 21

Illumina: Strengthening Competitive Position, Relevance And A Very Compelling Valuation

Jul 23

Illumina, Inc.'s (NASDAQ:ILMN) Share Price Could Signal Some Risk

Jul 01
Illumina, Inc.'s (NASDAQ:ILMN) Share Price Could Signal Some Risk

Illumina: Marriage Made In Hell Is (Finally) Over - Assessing Impact Of GRAIL Spin-Out

Jun 28

Should You Investigate Illumina, Inc. (NASDAQ:ILMN) At US$106?

May 26
Should You Investigate Illumina, Inc. (NASDAQ:ILMN) At US$106?

Illumina: Expect A Slow Rebound

May 07

Calculating The Fair Value Of Illumina, Inc. (NASDAQ:ILMN)

Apr 26
Calculating The Fair Value Of Illumina, Inc. (NASDAQ:ILMN)

Revenues Not Telling The Story For Illumina, Inc. (NASDAQ:ILMN)

Mar 20
Revenues Not Telling The Story For Illumina, Inc. (NASDAQ:ILMN)

Illumina: Stagnant Revenues And Shrinking Margins Amidst Rising Competition

Feb 23

Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?

Jan 26
Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?

Illumina: Volatility Galore, But Not Much Prospect Of Progress In 2024

Jan 19

Revenue & Expenses Breakdown

How Illumina makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:ILMN Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
29 Sep 244,390-1,5851,3541,118
30 Jun 244,429-3,0441,3651,179
31 Mar 244,493-1,2901,6461,204
31 Dec 234,504-1,1611,6371,207
01 Oct 234,465-1,1251,5721,234
02 Jul 234,461-4,1861,7051,246
02 Apr 234,448-4,4871,6361,227
01 Jan 234,584-4,4041,6141,209
02 Oct 224,700-4,1531,6821,242
03 Jul 224,693-201,5101,187
03 Apr 224,6567011,5501,061
02 Jan 224,5267621,744914
03 Oct 214,2809071,351794
04 Jul 213,9667691,350696
04 Apr 213,4736301,114650
03 Jan 213,2396561,014609
27 Sep 203,238638813572
28 Jun 203,351693811551
29 Mar 203,556942835562
29 Dec 193,5431,002907575
29 Sep 193,458973874607
30 Jun 193,405938881615
31 Mar 193,397851877600
30 Dec 183,333826849568
30 Sep 183,243684798538
01 Jul 183,103648768513
01 Apr 182,936567732492
31 Dec 172,752725720500
01 Oct 172,594775692488
02 Jul 172,487741664480
02 Apr 172,424730652474
01 Jan 172,398454630458
02 Oct 162,371440624450
03 Jul 162,314430621423
03 Apr 162,253415597395
03 Jan 162,220462561362
27 Sep 152,141510533348
28 Jun 152,071486516334
29 Mar 151,979430506321
28 Dec 141,861353499306
28 Sep 141,736281478294
29 Jun 141,612219453279
30 Mar 141,511208430264
29 Dec 131,421125423249

Quality Earnings: ILMN is currently unprofitable.

Growing Profit Margin: ILMN is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ILMN is unprofitable, and losses have increased over the past 5 years at a rate of 55.7% per year.

Accelerating Growth: Unable to compare ILMN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ILMN is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-4.7%).


Return on Equity

High ROE: ILMN has a negative Return on Equity (-74.59%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 02:16
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/29
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Illumina, Inc. is covered by 58 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
James Francis MainwaringAtlantic Equities LLP
Catherine Ramsey SchulteBaird